Viral Vector

BIA Separations adds to Cornerstone vector development program

16-Oct-2019 By Vassia Barba

An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.

BIA Separations launches purification technology for AAV production

17-Sep-2019 By Vassia Barba

BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.

Viral vector manufacturing collaboration generates ‘tangible value’

27-Jun-2019 By Vassia Barba & Maggie Lynch

Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.

Catalent enters AAV vector production agreement with IVERIC bio

18-Jun-2019 By Maggie Lynch

Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.

German biotech opens US office to expand its global presence

05-Feb-2019 By Maggie Lynch

Sirion Biotech has opened a US-based office to support local gene therapy research and clinical development with viral vector contract manufacturing.

Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019

27-Sep-2018 By Melissa Fassbender

Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.